PT  - JOURNAL ARTICLE
AU  - Deal, Chad
AU  - Gideon, James
TI  - Recombinant human PTH 1-34 (Forteo): An anabolic drug for osteoporosis
DP  - 2003 Jul 01
TA  - Cleveland Clinic Journal of Medicine
PG  - 585--601
VI  - 70
IP  - 7
4099  - http://www.ccjm.org/content/70/7/585.short
4100  - http://www.ccjm.org/content/70/7/585.full
SO  - Cleve Clin J Med2003 Jul 01; 70
AB  - Forteo (teriparatide of rDNA origin), a genetically engineered fragment of parathyroid hormone, is the first of a new class of drugs to treat osteoporosis. The drug’s anabolic action increases bone turnover, stimulating osteoblasts to a greater extent than osteoclasts, and reducing both vertebral and nonvertebral fractures. However, a number of issues about its use remain unanswered.